Dulaglutide
Based on 1 publication(s) in Google Scholar
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 96%
- CAS. Nr.: 923950-08-7
- Molecular Weight:62561 (Glycosylation, Dominant form)
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dulaglutide
More
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
WB
-
Others
Biologische Aktivität
GLP-1 receptor[1]
Dulaglutide (50 nM and 100 nM; 24 h) ameliorates ox-LDL-induced oxidative stress and suppresses ox-LDL-induced mitochondrial dysfunction in human aortic endothelial cells (HAECs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human aortic endothelial cells (HAECs)
-
Concentration:50 nM, 100 nM
-
Incubation Time:24 hous
-
Result:Suppressed ox-LDL-induced reduction of cell viability and release of lactate dehydrogenase (LDH).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats and Transgenic mice[1]
-
Dosage:0, 0.05, 0.5, 1.5, or 5 mg/kg; 0, 0.3, 1, or 3 mg/kg
-
Administration:SC, twice week, for 93 weeks; SC, twice week, for 26 weeks
-
Result:Statistically increased diffuse C-cell hyperplasia and adenomas at ＞0.5 mg/kg.
Decreased Systemic exposures over time in mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 923950-08-7
-
Appearance Liquid
-
Molecular Weight 62561 (Glycosylation, Dominant form)
-
Color Colorless to light yellow
-
Synonyms
LY2189265
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Endocrinol Metab
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway. [Abstract]2022 Feb;37(1):74-83. PMID: 35144334
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Dulaglutide (Dula) inhibits palmitic acid (PA)-induced lipid accumulation in HepG2 cells. Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid accumulation were evaluated using Oil red O staining.
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Dula glycopeptide (Dula) reduced lipogenesis and triglyceride (TG) synthesis in palmitic acid (PA)-treated HepG2 cells and increased TG secretion. HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the mRNA expression levels of genes encoding sterol regulatory binding protein 1 (SREBP-1), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS).
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dulaglutide and 100 nM exendin (9–39), a GLP-1R antagonist, for 24 hours. FAM3A, GLP-1R, sirtuin 1 (SIRT1), phospho-adenosine monophosphate-activated protein kinase (p-AMPK), phospho-acetyl-CoA carboxylase (p-ACC), and peroxisome proliferator-activated receptor alpha (PPARα) levels were analyzed using Western blotting.
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Dulaglutide (Dula) inhibits lipid deposition and increases fatty acid oxidation via family with sequence similarity 3 member A (FAM3A). HepG2 cells transfected with 10 nM FAM3A small interfering RNA (siRNA) or control (Con) siRNA for 24 hours were pretreated with 400 μM palmitic acid (PA) for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid deposition was evaluated using triglyceride (TG) content assay.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Chang W, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019 Dec;116:73-79. [Content Brief]
[2]. Hertzel C Gerstein, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet [Content Brief]
[3]. Byrd RA, et al. Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor AgonistDulaglutide in Rodents. Endocrinology. 2015 Jul;156(7):2417-28. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Dulaglutide Related Classifications
HY-P0120 Related Classifications
Powered by Bioz